Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cardiovascular, Cardiac, Cardiology, Cardiometabolic Companies _ Imaging, Diagnostics, Health IT & Medical Devices
Tethys Bioscience

Organization & Developments: Tethys Bioscience

Parents

2010: Tethys, which has been marketing its test since the second quarter of 2009, had sold more than 27,000 through the end of 2010
2011: Air Force physicians, led by Lt. Col. Mark True, plan to enroll 600 pre-diabetic patients at six domestic Air Force bases (2011)
2011: Expects annual sales to double in 2011.
2011: Tethys Snags U.S. Air Force Support for Big Diabetes Prevention Study (2011)
2013: $100M startup Tethys BioScience seen shutting down (2013)
Had raised about $100 million in funding since it was founded in 2002
PreDx DRS has been validated by the Tethys Clinical Laboratory (TCL) in several large populations.
Tethys PreDx™ Diabetes Risk Score (DRS), a simple-to-use, multimarker blood test that enables accurate identification of patients who have a high risk of developing type 2 diabetes within five years.
The additional $23 million brings the total raised in the company's Series D round to $48 million
The test uses standard immunoassay formats, sample collection and shipment methods. Currently performed exclusively by the CLIA-certified TCL, the test generates a Diabetes Risk Score between 1 and 10 that corresponds to an absolute percentage risk of deve